Zai Lab (NasdaqGM:ZLAB) just shared new data from its global Phase 1 trial for zocilurtatug pelitecan in patients with advanced small cell lung cancer, as well as updates on its upcoming Phase 3 study. The fresh results and study progression are catching investor attention for a reason.

Zai Lab’s recent clinical data dropped against a backdrop of ongoing volatility for the stock. After spiking on positive trial news, the share price is still down 24.1% over the past month and off 14.2% on a one-year total return basis. While momentum has faded since earlier gains this year, patient enrollment ramping up for its Phase 3 study could renew investor optimism over the long run.

If today’s breakthrough has you curious about other healthcare innovators moving the needle, it’s worth exploring See the full list for free.

Given these clinical breakthroughs and the stock’s recent pullback, investors may be wondering whether Zai Lab is an undervalued growth story ready for a rebound or if expectations for future success are already priced in.

Most Popular Narrative: 52.8% Undervalued

With shares last closing at $26.13, the most widely followed narrative suggests Zai Lab’s fair value is more than double today’s price. The case for Zai Lab centers on execution across a deep pipeline, aggressive cost efficiencies, and regulatory wins in China’s rapidly expanding healthcare market.

“Multiple high-potential product launches and label expansions over the next 12 to 18 months (including VYVGART, bemarituzumab, KarXT, TIVDAK, Tumor Treating Fields), combined with a deep pipeline in oncology and immunology, are expected to significantly increase Zai Lab's addressable market and diversify revenue streams, supporting both top-line growth and future earnings.”

Want to know the real reason Zai Lab’s upside potential looks so dramatic? This narrative is built on a bold combination of blockbuster pipeline launches, market expansion, and ambitious profitability targets. The full story highlights which future milestones could significantly reshape how investors value the company and the single financial projection that makes analysts optimistic.

Result: Fair Value of $55.41 (UNDERVALUED)

However, Zai Lab’s reliance on external innovation and rising competition from both domestic and global biotechs could present challenges to the bullish outlook ahead.

Build Your Own Zai Lab Narrative

If you see the story differently or want to chart your own conclusions, it takes just a few minutes to build your version from the same data. Do it your way

A good starting point is our analysis highlighting 3 key rewards investors are optimistic about regarding Zai Lab.

Looking for More Winning Investment Ideas?

The market never stands still, and the best returns go to those who seek out new opportunities. Make your next smart move before others catch on. These screens are ready to show you what’s ahead.

• Tap into the explosive potential of artificial intelligence by checking out these 26 AI penny stocks shaping tomorrow’s most profitable sectors before the mainstream takes notice.
• Uncover undervalued gems with strong fundamentals and track record by starting with these 832 undervalued stocks based on cash flows trusted by savvy investors searching for real bargains.
• Maximize your income strategy. See how these 22 dividend stocks with yields > 3% are generating consistent yields above 3% for portfolios focused on steady returns.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.